ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES INCLUSION OF FUTURE MEDICAL COSTS IN HEALTH TECHNOLOGY ASSESSMENT GUIDELINES

Published Nov 2, 2016
Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel entitled, Should Health Technology Assessment Guidelines Recommend Inclusion of Future Medical Costs?, at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Andrew Briggs, DPhil, MSc, William R, Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK. Panelists for the issue panel included:
  • Alec Morton, PhD, Professor, Management Science, University of Strathclyde, Glasgow, UK
  • Pieter van Baal, PhD, Associate Professor, Institute for Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
  • Ad Antonisse, MSc, Director Economic Affairs (Market Access and Public Affairs), AstraZeneca, Zoetermeer, The Netherlands
This session explored whether health technology assessment (HTA) guidelines should recommend the inclusion of “unrelated future costs” of a medical technology. Recently, Dutch HTA guidelines were changed to recommend inclusion of future, unrelated medical costs. Currently, however, many HTA guidelines exclude future medical costs from an appraisal. For example, the costs of caring for a patient with dementia after preventing death from stroke would not be included in a cost effectiveness analysis of a thrombolysis treatment. The panelists presented the benefits and disadvantages of including future, unrelated costs in HTA guidelines. Alec Morton, PhD provided a summary of theoretical arguments for and against inclusion of future unrelated medical costs. Pieter van Baal, PhD reviewed approaches for how these future costs can be estimated in practice. Ad Antonisse, MSc provided the industry perspective on the issue. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×